• Technology

    By introducing internal covalent disulfide bonds, stable, soluble, and potent trimeric TNFSF ligands can be produced. Due to the high structural homology within the TNF superfamily, the FusionBio concept of disulfide cross-linking is broadly applicable to all TNFSF ligands where optimal in vivo signaling is desired.
  • 1
  • What We Offer
  • The FusionBio Advantage
The FusioBio technology generates stable covalent trimers of tumor necrosis factor superfamily ligands to be used alone or in combination immunotherapy with other agents.
The FusionBio technology is unique in that it creates stable trimeric ligands with potent activity but without any external additions or introduced immunogenicity problems.